BioNTech to Acquire Biotheus to Boost Oncology Strategy
3 hours ago · BioNTech to pay $800 million to acquire 100 percent of the issued share capital and up to $150 million in potential milestone payments Additional details will be shared at BioNTech’s Innovation ...
BioNTech to Acquire Biotheus in $950 Million Deal
3 hours ago · BioNTech has agreed to acquire biotechnology company Biotheus for $800 million up front and up to $150 million in milestone payments. ... Dow Jones Newswires is a market-moving financial and ...
Pfizer and BioNTech Announce Positive Topline Data for ...
Oct 26, 2023 · NEW YORK & MAINZ, GERMANY-- (BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced positive topline results from a Phase 1/2 study (NCT05596734) evaluating the safety, tolerability and immunogenicity of mRNA-based combination vaccine candidates for influenza and COVID-19 …
Pfizer-BioNTech COVID-19 Vaccine COMIRNATY®
Dec 11, 2020 · NEW YORK & MAINZ, Germany-- (BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the U.S. Food and Drug Administration (FDA) approved the Biologics License Application (BLA) for COMIRNATY ® (COVID-19 Vaccine, mRNA) to prevent COVID-19 in individuals 16 years of age and older.
Newsroom - BioNTech
Welcome to the BioNTech Newsroom. In this section you can find a variety of media materials and useful information to download. Media Downloads. Conference "Working Together to Promote Vaccine Equity for Africa", December 18, 2023. Africa Vaccine Equity Conference 1. Africa Vaccine Equity Conference 2. Africa Vaccine Equity Conference 3.
Pfizer and BioNTech Provide Update on mRNA-based …
Aug 16, 2024 · NEW YORK & MAINZ, Germany--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced top-line results from their Phase 3 clinical trial to evaluate the companies’ combined mRNA vaccine candidate against influenza and COVID-19 in healthy individuals 18-64 years of age. The ...
BioNTech pays $800M to take control of potential Keytruda killer
3 hours ago · Now, the biotech has struck a deal to gain full control of PM8002, a bispecific also known as BNT327. BioNTech is paying $800 million and committing up to $150 million in milestones to buy ...
BioNTech to Acquire Biotheus to Boost Oncology Strategy
3 hours ago · BioNTech to pay $800 million to acquire 100 percent of the issued share capital and up to $150 million in potential milestone payments ; Additional details will be shared at BioNTech’s ...
BioNTech buys China's Biotheus to support oncology strategy
3 hours ago · Nov 13 (Reuters) - German drugmaker BioNTech (22UAy.DE), opens new tab has agreed to acquire Chinese biotech company Biotheus to support its oncology strategy and gain full global rights to the ...
BioNTech strikes $950mn deal for Chinese drugmaker Biotheus
2 hours ago · BioNTech has acquired Chinese cancer drugmaker Biotheus in a near $1bn deal, as the Covid-19 vaccine maker taps into the country’s health sciences expertise to develop promising immunotherapy ...